Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,236 people get ALXA articles and Market Currents by email alert.
Get email alerts on ALXA »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
Alexza Pharmaceuticals Inc. - Special CallWed, May 8
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 1, 2013)
-
PR Newswire (Apr 22, 2013)
-
-
-
-
PR Newswire (Mar 26, 2013)
-
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Mar 6, 2013)
-
-
PR Newswire (Feb 25, 2013)
-
PR Newswire (Feb 21, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Alexza Pharmaceuticals: Forward Looking Approval Catalyst In PlayM. E. Garza • Wed, Dec 14, 2011 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Using Options To Benefit From The Binary Nature Of FDA DecisionsDavid Anber • Thu, Oct 18, 2012 -
-
-
-
4 Healthcare Stocks Breaking Out Mid-WeekTimeless Wealth • Thu, May 3, 2012 -
-
-
Alexza Pharmaceuticals Inc. - Special CallWed, May 8
-
Alexza Pharmaceuticals, Inc., Q3 2009 Earnings Call TranscriptMon, Nov 9, 2009
-
Alexza Pharmaceuticals, Inc. Q4 2008 Earnings Call TranscriptTue, Mar 10, 2009
-
Alexza Pharmaceuticals, Inc. Q3 2008 Earnings Call TranscriptTue, Nov 18, 2008
-
Alexza Pharmaceuticals, Inc. Q2 2008 Earnings Call TranscriptTue, Sep 2, 2008
-
Alexza Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptMon, May 12, 2008
-
Alexza Pharmaceuticals, Inc.Q4 2007 Earnings Call TranscriptMon, Mar 17, 2008
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 1, 2013)
-
PR Newswire (Apr 22, 2013)
-
PR Newswire (Mar 26, 2013)
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Mar 6, 2013)
-
PR Newswire (Feb 25, 2013)
-
PR Newswire (Feb 21, 2013)
-
PR Newswire (Jan 3, 2013)
-
at MarketWatch.com (Dec 24, 2012)
-
at MarketWatch.com (Dec 24, 2012)
-
at MarketWatch.com (Dec 21, 2012)
-
PR Newswire (Nov 6, 2012)
-
PR Newswire (Oct 18, 2012)
-
PR Newswire (Oct 17, 2012)
ALXA vs. ETF Alternatives
Company Description
We are a pharmaceutical company focused on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system, or CNS, conditions. All of our product candidates are based on our proprietary technology, the Staccato system. The... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Wednesday, May 8, 12:53 PM
Midday top 10 gainers: TRMD +68%. SYNM +35%. AFFY +35%. ALXA +25%. CSPI +21%. PSE +21%. NBG +20%. WBMD +18%. SCOK +17%. EA +16%.
Midday top 10 losers: FIO -25%. OCLR -23%. LIOX -18%. VCLK -17%. AXLL -16%. OCLS -15%. BTH -15%. SALM -13%. ACFC -12%. SNTA -12%. Comment! [On the Move] -
Wednesday, May 8, 9:17 AM
Premarket gainers: ALXA +51%. PSE +19%. LEDR +16%. NBG +11%. WFM +8%. EA +6%. PRTS +6%. SFUN +6%. CTSH +5%.
Losers: FIO -22%. VCLK -19%. OCLR -19%. AXLL -9%. CIE -7%. CHRW -7%. SODA -6%. DDD -6%. SYMC -5%. Z -5%. VVUS -5%. Comment! [On the Move] - Wednesday, May 8, 9:11 AM Alexza Pharmaceuticals (ALXA) comes off trading halt, now up 52% premarket following the license deal with Teva (TEVA +0.3% premarket). The conference call discussing the matter is underway. 3 Comments [Breaking News, Healthcare, On the Move]
- Wednesday, April 3, 11:03 AM Alexza Pharmaceuticals (ALXA +4%) gives back a little but remains firmly in the green following a +7% run-up during the pre-open session on an earlier upgrade from Piper Jaffray to Overweight. Piper notes that it's channel checks with ER physicians, psychiatrists, and opinion leaders was even more encouraging than it expected on both the near and longer-term market potential for Adasuve versus previous projections. Additionally, it's clinical attributes bode well for a value-added partnership being signed soon to enable effective launch in Q3. 1 Comment [Healthcare, On the Move]
-
Wednesday, April 3, 9:10 AM
Premarket gainers: CALL +14%. CONN +10%. ZNGA +10%. ASTX +10%. UNXL +9%. AWRE +9%. OMPI +9%. NVAX +9%. ALXA +8%. MHR +7%. NFX +6%.
Losers: MSPD -19%. GPN -7%. 3 Comments [On the Move] -
Thursday, February 21, 9:10 AM
Premarket gainers: PRKR +38%. RPRX +31%. NVGN +28%. BRY +22%. PEGA +17%. LOCK +7%. LNCO +5%. ALXA +5%.
Losers: GENT -37%. PAY -34%. GFI -17%. ALU -7%. WLT -6%. TSLA -5%. Comment! [On the Move] -
Monday, December 24, 2012, 2:57 PM
After-hours top gainers, as of 2:30 p.m.: TVIX +3.6%. UVXY +3.1%. VXX +1.9%. SE +1.6%. ALXA +1.6%.
After-hours top losers: UGAZ -2.1%. XIV -1.7%. SVXY -1.7%. AIG -1.6%. ABB -1.3%. Comment! [On the Move] -
Monday, December 24, 2012, 11:15 AM
Midday top 10 gainers: ATV +34%. CT +18%. ALIM +12%. CLSN +12%. EJ +11%. EDAP +11%. GSS +11%. RGLS +10%. AVEO +10%. EGLE +10%.
Top 10 Losers: MHH -30%. TLAB -27%. ALXA -14%. XRTX -12%. AMPL -11%. CIG -10%. SVA -9%. ISS -9%. MITL -8%. RPTP -8%. 1 Comment [On the Move] - Monday, December 24, 2012, 9:10 AM Premarket Losers: TLAB -26%. ALXA -11%. Comment! [On the Move]
- Friday, December 21, 2012, 7:26 PM The FDA's approval of Alexza Pharmaceutical's (ALXA) Adasuve comes with several post-approval requirements, including a large observational clinical trial to gather patient safety data based on real-world use, as well as a clinical program addressing the safety and efficacy of the drug adolescent patients. Shares -11% AH. 8 Comments [Healthcare, On the Move]
-
Friday, December 21, 2012, 5:38 PM
After-hours top gainers, as of 5:15 p.m.: TFSL +6%. PACT +3%. PBRA +3%. DANG +3%. OIBRC +2%.
After-hours top losers: ALXA -13.13%. PATH -7%. SVU -4%. TXT -4%. NSU -4%. 1 Comment [On the Move] - Friday, December 14, 2012, 9:27 AM Alexza Pharmaceuticals (ALXA) and Grupo Ferrer Internacional say the Committee for Medicinal Products for Human Use delivered a positive opinion on recommending European marketing of Adasuve, their treatment for schizophrenia and bipolar disorder. ALXA +19.1% premarket. 1 Comment [Healthcare, On the Move]
-
Friday, December 14, 2012, 9:10 AM
Premarket gainers: ALXA +18%. ALU +10%. TIVO +5%. ADBE +5%.
Losers: CYTX -15.66%. CNC -8%. BBY -8%. PAY -7%. ISIS -6%. FBR -5%. Comment! [On the Move] -
Tuesday, December 11, 2012, 6:10 PM
After-hours top gainers, as of 5:15 p.m.: RTEC +8%. DLB +6%. MCBC +4%. BGMD +4%. GEO +3%.
After-hours top losers: GEOS -12%. CIE -10%. EXAR -7%. NTSP -7%. ALXA -7%. 1 Comment [On the Move] -
Tuesday, December 4, 2012, 9:10 AM
Premarket gainers: SINO +28%. GALE +14%. FHCO +10%. BIG +7%. OCZ +6%. ALXA +5%.
Losers: GERN -28%. PBY -9%. DRI -9%. SSN -6.4%. PCS -6.4%. Comment! [On the Move] - Monday, November 19, 2012, 1:07 PM Alexza Pharmaceuticals (ALXA +4.5%) gains on its announcement earlier today that a CHMP Day 180 Second List of Outstanding Issues from the European Medicines Agency found no objections regarding its Marketing Authorization Application for its schizophrenia treatment Adasuve. There were two major objections outlined in the CHMP's initial release, which appear to have been resolved. ALXA expects to receive its Day 210 EMA Opinion in December. Comment! [Healthcare, On the Move]
-
Ryan Mallory
Fuinhaz Setups for May 15 2013 | $ACAD $ALXA $CETV $CSIQ $SCTY $SODA $SPU | SharePlanner http://bit.ly/13xbTQb - View all 0 replies
-
- View all 0 replies
-
- View all 3 replies
-
Perkins Cove: Ohhh...yah.....up 45% to $6.30+ ....congrats ALXA holders. Anybody here get that nice jump?
-
-
- View all 0 replies
-
Jason F
Nothing Bullish About $ALXA stock chart. Really bearish chart. http://bit.ly/WOKzrE (analysis in the link) - View all 0 replies
-
- View all 1 replies
-
-
emeickhoff
I think its halted to prevent the short sellers to destroy the price on approval. This is a good sign $ALXA - View all 1 replies
-
-
- View all 0 replies
-
Jason F
My $ALXA Run Down Targets -Chart Analysis - http://bit.ly/XWgkhe (On the site I posted a chart saying yesterday was time to sell) - View all 1 replies
-
Jason F: I think on one of the articles or stocktalks yesterday I wrote time to sell ALXA. The TA on the chart provided warning signs.
-
- View all 13 replies
-
-
LATEST REPLIES
-
- View all 3 replies
-
Perkins Cove: Ohhh...yah.....up 45% to $6.30+ ....congrats ALXA holders. Anybody here get that nice jump?
-
-
- View all 13 replies
-
-
-
- View all 5 replies
-
Scott Matusow: Zacks analyst wrote a negative piece which I find to be partly disingenuous.
-
u681694: Scott - what's your opinion on where ALXA is heading over the short - medium term?
-
- View all 1 replies
-
-
emeickhoff
I think its halted to prevent the short sellers to destroy the price on approval. This is a good sign $ALXA - View all 1 replies
-
-
- View all 6 replies
-
medic11: Same s@#t, different pile. Stock is down post approval. Just like AMRN.
-
JMEaramn: Any ballparks as to how the restrictions are going to affect the stock price?
-
Jason F
My $ALXA Run Down Targets -Chart Analysis - http://bit.ly/XWgkhe (On the site I posted a chart saying yesterday was time to sell) - View all 1 replies
-
Jason F: I think on one of the articles or stocktalks yesterday I wrote time to sell ALXA. The TA on the chart provided warning signs.
-
- View all 3 replies
-
foldholder: why is the stock moving down today? how higher will it reach by 21st?
-
JMattius: No FDA news until Friday so I expect a bit of a slow bleed leading up to Friday. Weak hands may be selling as well.
-
reachmygoals1
$ALXA has chances to go 2 for 2 this month-Eu decision & FDA decision.Last month, manufacturing facility was inspected and satisfactory. - View all 3 replies
-
foldholder: $ALXA has a new article http://seekingalpha.com/a/mohd. Does it still make sense to buy this stock?
-
JMattius: Buy if you feel it will get approved. Sell or stay away if you don't. No article can predict what the FDA is going to do.
-
- View all 3 replies
-
freefdawatchlist: don't buy more, because if fda delay it by 3 month, the stock may drop. Check out other stock which haven't rallied up till now.
-
